Psykey, Inc. (CEOS) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist Psykey, Inc. (CEOS) ein Healthcare-Unternehmen mit einer Bewertung von 0. Die Aktie erzielt 68/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 17. März 2026Psykey, Inc. (CEOS) Gesundheitswesen & Pipeline-Uebersicht
Psykey, Inc., formerly CeCors, Inc., operates in the healthcare sector, focusing on entheogenic and adaptogenic ingredients for functional products. The company develops technologies for targeted delivery of entheogen-based therapeutics and offers retail products like mushroom-infused beverages and supplements, positioning itself in the emerging psychedelic market.
Investmentthese
Psykey, Inc. presents a speculative investment opportunity within the emerging psychedelic therapeutics and functional ingredients market. The company's focus on developing technologies for targeted delivery of entheogen-based therapeutics could be a key value driver, contingent on successful research and regulatory approvals. With a market capitalization of $0.00B and a negative P/E ratio of -2.38, the company's financial performance is currently weak, indicated by a negative profit margin of -5.6%. However, a high gross margin of 99.6% suggests potential for profitability if sales volume increases. Key growth catalysts include successful product launches and advancements in their therapeutic technologies. The investment thesis hinges on Psykey's ability to capitalize on the growing interest in psychedelic medicine and functional foods.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market Cap of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- P/E Ratio of -2.38 reflects current losses, suggesting the company is in a growth phase and not yet profitable.
- Gross Margin of 99.6% demonstrates strong pricing power and efficient cost management in its product lines.
- Profit Margin of -5.6% highlights the need for improved operational efficiency and increased sales to achieve profitability.
- Beta of 0.63 suggests the stock is less volatile than the overall market, potentially offering some stability in a turbulent sector.
Wettbewerber & Vergleichsunternehmen
Staerken
- Focus on emerging markets of entheogenic and adaptogenic ingredients.
- Development of innovative delivery technologies.
- Diverse product lines including functional beverages and supplements.
- High gross margin.
Schwaechen
- Limited market capitalization.
- Negative profit margin.
- Reliance on research and development for future growth.
- Limited brand recognition.
Katalysatoren
- Upcoming: Potential regulatory approvals for entheogen-based therapeutics could significantly boost investor confidence and market valuation.
- Ongoing: Expansion of product lines and market reach in the functional food and beverage sector.
- Ongoing: Strategic partnerships with research institutions and pharmaceutical companies to accelerate development and commercialization.
Risiken
- Potential: Regulatory hurdles and uncertainty surrounding entheogen-based products could delay or prevent commercialization.
- Potential: Intense competition in the functional food and psychedelic markets could limit market share and profitability.
- Ongoing: Limited market capitalization and negative profit margin pose financial sustainability risks.
- Ongoing: Dependence on research and development for future growth exposes the company to technological and clinical trial risks.
Wachstumschancen
- Expansion of Product Lines: Psykey can capitalize on the growing demand for functional foods and beverages by expanding its product lines to include a wider range of mushroom-infused products and supplements. The global functional food market is projected to reach $267.92 billion by 2027, offering a substantial opportunity for Psykey to increase its market share through innovative product development and targeted marketing campaigns. Timeline: 1-2 years.
- Development of Entheogen-Based Therapeutics: Psykey's research and development efforts in entheogen-based therapeutics could lead to the development of novel treatments for mental health disorders. The psychedelic therapeutics market is projected to reach $10.75 billion by 2027, presenting a significant growth opportunity for Psykey if it can successfully navigate regulatory approval processes and commercialize its therapeutic technologies. Timeline: 3-5 years.
- Strategic Partnerships and Collaborations: Psykey can accelerate its growth by forming strategic partnerships with research institutions, pharmaceutical companies, and distribution networks. Collaborations can provide access to new technologies, funding, and market channels, enabling Psykey to expand its reach and accelerate the development and commercialization of its products. Timeline: Ongoing.
- Geographic Expansion: Psykey can expand its geographic presence by targeting new markets in North America, Europe, and Asia. The global market for functional foods and psychedelic therapeutics is growing rapidly, offering opportunities for Psykey to establish a presence in new regions and increase its customer base. Timeline: 2-3 years.
- Intellectual Property Protection: Psykey can strengthen its competitive advantage by securing intellectual property protection for its innovative formulations and technologies. Patents and trademarks can provide exclusive rights to its products and processes, preventing competitors from replicating its offerings and enhancing its market position. Timeline: Ongoing.
Chancen
- Expansion into new geographic markets.
- Strategic partnerships with research institutions and pharmaceutical companies.
- Increasing consumer demand for functional foods and alternative therapies.
- Potential for regulatory approval of entheogen-based therapeutics.
Risiken
- Intense competition in the functional food and psychedelic markets.
- Regulatory hurdles and uncertainty surrounding entheogen-based products.
- Potential for adverse side effects from entheogenic ingredients.
- Fluctuations in raw material costs.
Wettbewerbsvorteile
- Proprietary formulations of entheogenic, adaptogenic, and nootropic ingredients.
- Development of targeted delivery technologies for entheogen-based therapeutics.
- Early mover advantage in the emerging psychedelic market.
Ueber CEOS
Psykey, Inc., founded in 2002 and based in Toronto, Canada, is a healthcare company engaged in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients. These ingredients are used in their functional product lines, which aim to improve and optimize life. The company also develops technologies focused on the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the burgeoning psychedelic market. Psykey's retail offerings include functional mushroom coffees and teas, oral supplements, and single-serve drink mixes. Formerly known as CeCors, Inc., the company rebranded as Psykey, Inc. in August 2021, signaling its strategic shift towards psychedelic and functional ingredients. This transformation reflects the company's commitment to innovation in the health and wellness sector, particularly in areas related to mental health and cognitive enhancement. Psykey's focus on research and development aims to create novel therapeutic solutions and consumer products that leverage the potential benefits of entheogens and adaptogens.
Was das Unternehmen tut
- Researches and develops entheogenic ingredients.
- Researches and develops adaptogenic ingredients.
- Researches and develops nootropic ingredients.
- Formulates functional product lines.
- Develops technologies for targeted delivery of entheogen-based therapeutics.
- Offers functional mushroom coffees and teas.
- Offers oral supplements.
- Offers single-serve drink mixes.
Geschaeftsmodell
- Develops and sells functional food and beverage products containing mushroom extracts and other adaptogens.
- Researches and develops technologies for the delivery of entheogen-based therapeutics.
- Generates revenue through direct-to-consumer sales and partnerships with retailers.
Branchenkontext
Psykey, Inc. operates within the rapidly evolving market for functional foods and psychedelic therapeutics. The industry is experiencing increased interest in alternative treatments for mental health and wellness, driving demand for products containing entheogenic and adaptogenic ingredients. This market is characterized by intense competition, with numerous companies vying for market share. Psykey's focus on research and development aims to differentiate itself through innovative formulations and targeted delivery technologies. The company's success will depend on its ability to navigate regulatory hurdles and establish a strong brand presence in a competitive landscape.
Wichtige Kunden
- Health-conscious consumers seeking functional food and beverage products.
- Individuals interested in the potential benefits of adaptogens and nootropics.
- Patients seeking alternative treatments for mental health disorders (future).
Finanzdaten
Chart & Info
Psykey, Inc. (CEOS) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer CEOS verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CEOS.
Kursziele
Wall-Street-Kurszielanalyse fuer CEOS.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CEOS auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Michael Maher
CEO
Michael Maher is the CEO of Psykey, Inc., leading a team of six employees. His background includes experience in managing and developing companies within the health and wellness sector. Maher's expertise lies in identifying emerging market trends and translating them into viable business strategies. He has a track record of driving innovation and growth in companies focused on functional ingredients and therapeutic solutions. Maher's leadership is focused on advancing Psykey's research and development efforts and expanding its market presence.
Erfolgsbilanz: Under Michael Maher's leadership, Psykey, Inc. has focused on developing technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics. He oversaw the rebranding from CeCors, Inc. to Psykey, Inc. in August 2021, signaling a strategic shift towards the psychedelic market. Maher's tenure has been marked by efforts to expand the company's product lines and establish partnerships within the industry.
CEOS OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Psykey, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier involves higher risks due to the potential for limited information and liquidity compared to listed companies.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited liquidity due to low trading volume.
- Lack of regulatory oversight and financial reporting requirements.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Information asymmetry due to limited public information.
- Verify the company's financial statements and disclosures.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and regulatory compliance.
- Determine the company's capital structure and funding sources.
- Monitor the company's trading volume and price volatility.
- Consult with a qualified financial advisor.
- Company's history of operations since 2002.
- Focus on research and development of innovative products.
- Presence in the emerging market for functional foods and psychedelic therapeutics.
- Management team with experience in the health and wellness sector.
CEOS Healthcare Aktien-FAQ
What are the key factors to evaluate for CEOS?
Psykey, Inc. (CEOS) currently holds an AI score of 68/100, indicating moderate score. Key strength: Focus on emerging markets of entheogenic and adaptogenic ingredients.. Primary risk to monitor: Potential: Regulatory hurdles and uncertainty surrounding entheogen-based products could delay or prevent commercialization.. This is not financial advice.
How frequently does CEOS data refresh on this page?
CEOS prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CEOS's recent stock price performance?
Recent price movement in Psykey, Inc. (CEOS) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on emerging markets of entheogenic and adaptogenic ingredients.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CEOS overvalued or undervalued right now?
Determining whether Psykey, Inc. (CEOS) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CEOS?
Before investing in Psykey, Inc. (CEOS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CEOS to a portfolio?
Potential reasons to consider Psykey, Inc. (CEOS) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Focus on emerging markets of entheogenic and adaptogenic ingredients.. Additionally: Development of innovative delivery technologies.. The AI-driven MoonshotScore of 68/100 reflects solid quantitative fundamentals. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CEOS?
Yes, most major brokerages offer fractional shares of Psykey, Inc. (CEOS) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CEOS's earnings and financial reports?
Psykey, Inc. (CEOS) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CEOS earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data as of March 17, 2026.
- OTC market data may be limited or inconsistent.
- Analyst coverage may not be available for this stock.